Roche Holding Ltd RO
SIX · Switzerland · Health Technology
CHF 356.40-4.40 (-1.22%)
Market open· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Market open· · CHF · Data may be delayed
Prices may be delayed and are for informational purposes only - not investment advice.
Total return, dividends included.
Where the price sits against its 50- and 200-day moving averages.
Makkler Fair Value, financial health score, analyst view, peers and MakklerAI.
The FDA has accepted fenebrutinib for priority review across two forms of multiple sclerosis following three Phase III studies, moving Roche toward a potential expansion of its MS portfolio beyond Ocrevus. Key Investor TakeawaysGenentech, part of Roche Group (USOTC:RHHBY), has received FDA priority review for fenebrutinib in both relapsing multiple sclerosis and primary progressive multiple sclerosis.
Roche is increasingly looking like a notable contender in this fast-growing area.
Recent third-party headlines about this company, kept separate from Makkler's own editorial coverage and linking out to the publisher. Accuracy is the publisher's responsibility.